-+ 0.00%
-+ 0.00%
-+ 0.00%
Pfizer, BioNTech win FDA approval for XFG-adapted COVID-19 vaccine in high-risk US adults
Share
Listen to the news
Pfizer, BioNTech win FDA approval for XFG-adapted COVID-19 vaccine in high-risk US adults
  • FDA cleared Pfizer’s supplemental filing for an XFG-adapted COMIRNATY COVID-19 shot for the 2026-2027 season.
  • Authorization covers adults 65+ plus ages 5-64 with at least one high-risk underlying condition.
  • Shipments start immediately, supporting near-term seasonal demand in the U.S. market.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BioNTech SE published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608271630PRIMZONEFULLFEED1001259770) on August 27, 2026, and is solely responsible for the information contained therein.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending